ライフサイエンスコーパス: cost saving

1 d employees (fewer handovers, less overtime, cost savings).

2 sles and rubella eradication is feasible and cost saving.

3 vity analysis showed 79% of simulations were cost saving.

4 was the most effective intervention and was cost saving.

5 act of telemedicine in the ICU and potential cost saving.

6 population level, upfront genotyping seemed cost saving.

7 tment was significantly effective, safe, and cost saving.

8 k towards these shift patterns as a means of cost saving.

9 s did not indicate that the questionnaire is cost saving.

10 t HPV vaccination program is predicted to be cost saving.

11 monitoring after PCI can lead to substantial cost saving.

12 20% with MAT+ 80% was most effective and was cost saving.

13 oritized PrEP, while risk prioritization was cost-saving.

14 P screening and treatment program was highly cost-saving.

15 procure DAAs at a price where they would be cost-saving.

16 We predict that this policy would be cost-saving.

17 Strategies to reduce shocks could result in cost savings.

18 ce was associated with improved survival and cost savings.

19 could improve outcomes and produce long-term cost savings.

20 of children with IF and was associated with cost savings.

21 examinations, which resulted in substantial cost savings.

22 metrics in strategies for risk reduction and cost savings.

23 cancer with consequent potential health care cost savings.

24 erms of lesser intervention of operators and cost savings.

25 antial improvements in clinical outcomes and cost savings.

26 ve complications could result in substantial cost savings.

27 s estimated to have resulted in $8,108.84 of cost savings.

28 ing while bringing significant computational cost savings.

29 care use and disability, resulting in major cost savings.

30 important for future disease management and cost savings.

31 t in high-temperature systems for energy and cost savings.

32 erall, LT does not provide glaucoma-specific cost savings.

33 have the potential to result in significant cost savings.

34 , shorter hospitalization, and a significant cost savings.

35 n dollars (AUD) and generated AUD$147 500 in cost savings.

36 uses annually, which would result in overall cost savings.

37 gh patient satisfaction, and, in some cases, cost savings.

38 s use 450 mg/day due to reported success and cost savings.

39 ove patient outcomes and lead to substantial cost savings.

40 cal care requires both high-quality care and cost savings.

41 outcomes and was associated with substantial cost savings.

42 d cancer drug prescribing, but may not yield cost savings.

43 aerosolized RBV, with potential significant cost savings.

44 ial for reduction in hospital admissions and cost savings.

45 e cost AUD$349,000 and generated $147,500 in cost savings.

46 trategy that may also allow for considerable cost savings.

47 f NSQIP and its interventions from the gross cost-savings.

48 unusual ingredients and thus help to achieve cost-savings.

49 ant health gains and healthcare and societal cost-savings.

50 oved the ICER to $6,200/QALY gained (95% CI, cost-saving $24,300).

51 The clinic efficiency and cost savings achieved by eliminating formal visual acuit

52 id diagnostic tests in antenatal care can be cost-saving across countries with varying HIV prevalence

53 improvements in wellbeing-rather than merely cost savings-again depends on the ethical approach to va

54 Cost-savings analysis was performed.

55 that the intervention resulted in both a net cost savings and a net increase in QALYs.

56 afforded significant advantages in terms of cost savings and adverse events averted compared with IV

57 iver sizeable health gains and health sector cost savings and are likely to reduce health inequalitie

58 Vaccination resulted in more cost savings and better outcomes at higher attack rates.

59 e potentially offering other benefits (e.g., cost savings and environmental impact reduction).

60 is adjusted approach will enable substantial cost savings and facilitate reaching programmatic goals

61 bsidies and incentives that do not encourage cost savings and good performance, insurance policies th

62 c substitutions result in minimal additional cost savings and have an inherent risk of medication err

63 Authors reported state-specific cost savings and instances of increased access or qualit

64 HIV-infected patients would result in modest cost savings and likely reduce patient anxiety, with lit

65 rting with short oligos remain important for cost savings and pedagogical benefit.

66 ay discharge was associated with significant cost savings and was preferred by patients.

67 ART initiations per month), POC testing was cost-saving and at lower clinic volumes (20 ART initiati

68 itivity Analysis: Individualized control was cost-saving and generated more QALYs compared with unifo

69 Screening using bead-based assay is cost-saving and improves graft outcomes.

70 Ambulatory surgery offers significant costs savings and generally superior 30-day outcomes rel

71 ombined with linkage to addiction treatment (cost saving), and naloxone distribution combined with Pr

72 nt is highly beneficial for quality of life, cost saving, and cost-effectiveness in the United States

73 reduction in delay to treatment, health care cost savings, and decrease in no-show rate.

74 be tailored for cultural competence, can be cost-saving, and can help to address the unmet needs of

75 ns that demonstrate maximum benefit could be cost-saving, and complete nonuse could lead to financial

76 ing prevents inappropriate HIV diagnosis, is cost-saving, and should be adopted in all EID programmes

77 l will result in better patient outcomes and cost-savings, and remains cost-effective if only a fract

78 ction in the force, result in a small system costs savings, and decrease the threat of transfusion-tr

79 tests together with the concept of time and cost saving are pushing the development of portable, min

80 0,879-US$1.6 million) per year; 80% of these cost savings are due to reductions in benefit payments a

81 Most cost savings are expected to accrue to Medicare, and mos

82 that includes only direct medical costs, the cost savings are S$144 per person.

83 high-throughput applications, the potential cost savings associated with 3'-DGE approach are likely

84 are polyclinics, the present value of future cost savings associated with the telemedicine-based mode

85 nnish Asthma Program resulted in significant cost savings at both the societal and patient levels dur

86 enzymatic concentration and, hence, offers a cost-saving benefit.

87 for mental health care may lead not only to cost savings but also to negative downstream consequence

88 ing patients with existing CNV in one eye is cost saving, but monitoring is generally not cost-effect

89 rm such functions can be advantageous due to cost savings, but when they are essential for growth, or

90 waZulu-Natal could be very cost-effective or cost-saving, but suboptimal PrEP would erode benefits an

91 s were estimated with >80% probability to be cost saving by 2023.

92 consumer response alone was estimated to be cost-saving by 2023, with net lifetime savings of $10.42

93 its of pulse oximeters and possible hospital cost-savings by targeting oxygen therapy might not be re

94 ts (10 990 DALYs averted per year) and to be cost-saving (by $2.9 million per year), leading to a red

95 ided fluoropyrimidines treatment represent a cost-saving choice for individuals suffering from cancer

96 Over 5 years, bariatric surgery was cost saving compared to BMT (total cost GBPpound 22,057

97 COL was cost saving compared to No Screening.

98 An antiviral prophylaxis strategy was cost saving compared to the current strategy and should

99 tion plus linkage to addiction treatment was cost saving compared with no additional intervention (gr

100 bined with linkage to addiction treatment is cost saving compared with no additional services.

101 The model predicts Aprokam is cost saving compared with purchased PFS, with a modest i

102 a catch-up campaign of 1- to 4-year-olds is cost saving compared with the reactive strategy, both wi

103 in absenteeism and benefit payments lead to cost savings compared to a scenario of no treatment prov

104 is, it provided superior health outcomes at cost savings compared to the pretransplant DAA treatment

105 Pharmacy purchasing data underestimated cost savings compared with EMR and PHIS data, while EMR

106 s is not only more accurate than but is also cost-saving compared to conventional culture methods.

107 Eradication of polio would likely be cost-saving compared to permanent control.

108 th any COVID-19-consistent symptoms would be cost-saving compared to testing only those whose symptom

109 over a 10-year period and is expected to be cost-saving compared with current control efforts.

110 ts and rebubble rates revealed that DMEK was cost-saving compared with DSAEK in 38% of iterations and

111 VL failure confirmation was cost-saving compared with SOC.

112 e visit with a dual rapid diagnosis test was cost-saving compared with the base case in all four coun

113 both standard PrEP and long-acting PrEP were cost saving, compared with no PrEP.

114 Cost analysis and potential cost savings comparing PR to scleral buckle and vitrecto

115 n a high-wind scenario, resulting in a 6-20% cost savings, depending on the avoided conventional tech

116 vaccine (8.1499 QALYs [0.5697]) and, due to cost savings, dominated standard-dose vaccine in the cos

117 Univariate sensitivity analyses demonstrated cost-savings down to a PF rate of 5.6%, up to a relative

118 tive care have reported a general pattern of cost savings during inpatient hospital admissions and th

119 Polypill patients commented frequently on cost-savings, ease, and convenience of a daily-dosing pi

120 oosing an appropriate design can yield large cost savings especially when multiplexed workflows are c

121 wet season, malaria preventive treatment was cost saving even when average daily bed-stay costs were

122 The QUENCHER method is a time and cost-saving extraction-free procedure measuring in vitro

123 Sexual outcomes, morbidity profiles and cost-savings favour intermittent therapy in most randomi

124 ccination, and the vaccine interventions are cost saving for all age and risk groups.

125 cts of patients with Ebola virus disease was cost saving for contacts of all ages in Liberia, Sierra

126 ary, redistricting appears to be potentially cost saving for the health care system but will increase

127 <$100 000/measles case averted) or was even cost saving for travelers to hot spots, especially if tr

128 The theoretical total cost savings for 2013, comparing actual with predicted c

129 aden patient access to biologics and provide cost savings for health care systems.

130 costs and, in India and China, produced net cost savings for most interventions under a societal per

131 lementation is independently associated with cost savings for pancreatoduodenectomy.

132 Biosimilars promise significant cost savings for patients, but the unavoidable differenc

133 centres, as well as bringing convenience and cost savings for the patient and service provider.

134 could generate substantial health gains and cost savings for the US population.

135 d utilizing NSQIP appear to be effective and cost-saving for AHS.

136 avoided 1044 scans, potentiating significant cost-saving for maternity services.

137 etary expenditures for the government but is cost-saving for patients at high risk of AMD.

138 ecrease with decreasing DAA prices, becoming cost-saving for the base price (euro15,000) discounts of

139 Iodine supplementation was cost saving from both a health service perspective (savi

140 as the cost of implementing the bundle minus cost savings from fewer infections.

141 ART has resulted in substantial cost savings from OIs averted.

142 th the most extreme phenotypes and potential cost savings from pooled tests of the extreme tails, wit

143 ffer reduced susceptibility to CO poisoning, cost savings from reduced precious metal usage, opportun

144 osimulation model, we explored the potential cost savings from the hospital system perspective under

145 e ezetimibe becomes generic, and may lead to cost savings from the perspective of the healthcare syst

146 The present value of total lifetime cost savings from the policy change is estimated to be U

147 Among MSM in San Diego, EarlyTest was cost-savings (ie, ICERs per AHI diagnosis less than $13.

148 most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500.

149 Routine pediatric EV71 vaccination would be cost-saving if the all-inclusive EVC is below US$10.6 (9

150 s plane showed that restrictive strategy was cost saving in 89.1%, but resulted in less pain-free pat

151 leads to a significant performance gain and cost saving in comparison with conventional methods to t

152 pyramid, the intervention is expected to be cost saving in contacts of all age groups in areas with

153 90% coverage in this way was estimated to be cost saving in five of the six regions (and in 40 of 46

154 The program was cost saving in patients with suspected infection (-$272,

155 the ICU is cost-effective in most cases and cost saving in some cases.

156 dren in LMICs, and estimated large potential cost savings in OIs averted with ART use, although there

157 frequency of viral load monitoring may offer cost savings in resource limited settings.

158 frequency of viral load monitoring may offer cost savings in resource-limited settings.

159 rifampicin resistance can lead to long-term cost savings in second-line treatment and (ii) its highe

160 may improve health utility and could produce cost savings in the first year after percutaneous corona

161 However, teduglutide therapy was cost-saving in 13% of model iterations.

162 ew York City) by 2030, at ICERs ranging from cost-saving in Atlanta, Baltimore, and Miami, to $95 416

163 eat benefit in clinical practice and a large cost-saving in clinical trial recruitment.

164 d to estimate the price at which DAAs become cost-saving in Japan.

165 a or alpha 2b plus ribavirin was dominant or cost-saving in Thailand compared to a palliative care.

166 MSM in the UK is cost-effective and possibly cost-saving in the long term.

167 might be cost-effective far sooner, and even cost-saving, in settings where long-term health-care cos

168 We discuss the relative impacts of both cost-savings information and environmental health messag

169 Currently available standard PrEP is a cost-saving intervention whose delivery should be expand

170 ared with IVR and IVA compared with IVR were cost-saving interventions (ICER, <0) regardless of the p

171 ostic tools, and available cost-effective or cost-saving interventions.

172 These probabilistic analyses projected that cost saving is achieved 37% of 1,000 iterations.

173 Cost saving is also feasible if the per-patient per-hosp

174 The qHPV vaccination strategy was cost saving; it decreased lifetime costs by $419 and inc

175 Additionally, these cost savings may be most prominent amongst the patients

176 for the detection of sequence variants as a cost saving measure.

177 self-taken samples could be an effective and cost-saving method, with high negative predictive values

178 primary outcome was the expected per-patient cost savings (microbiology, pharmacy, and indirect hospi

179 Additionally, some cost savings might be achieved if symptoms could be util

180 an AHS perspective using this formula: Gross cost-savings = N * (p1 - p2) * unit cost, where N was th

181 The intervention was estimated to be cost saving (net cost <0 AUD) or cost-effective (i.e., I

182 4 to 0.044) and a 73.7% probability of being cost-saving (net cost, -C$389.00; 95% CI, -C$1712.00 to

183 cost-saving to cost-effective, with maximum cost savings occurring when a hospital uses more expensi

184 s of 2.8k (SD, 14.5k) per patient and an ICU cost saving of 25%.

185 imus borneensis), and achieve an opportunity cost saving of over US$43 billion.

186 The second aim was to examine potential cost saving of telemedicine in the ICU through probabili

187 surgery, could translate to an annual total cost saving of up to $1.4 million across the four partic

188 o clozapine indicated a potential healthcare cost saving of ~pound 3400 (equivalent to $4232 USD) per

189 stay by 1.6 days (P = 0.002), and a hospital cost savings of $1492 per patient (P = 0.01).

190 symptomatic horseshoe tear resulted in a net cost savings of $1749 ($1314) and improved utility, wher

191 cost-effective, based on the estimated labor cost savings of $2,132.71 for each percent increase in t

192 dstream infection, for an approximate annual cost savings of $2.34 million.

193 (2.62 billion to 3.92 billion) and societal cost savings of $2.64 billion (2.13 billion to 3.28 bill

194 This resulted in cost savings of $20.28 per patient, reduction of wait ti

195 n rate of 6%, ISDD use was associated with a cost savings of $272 (3%) per blood culture in terms of

196 This resulted in cost savings of $35.68 per patient, shortened wait-time

197 idence interval [CI], 828 032-874 853), with cost savings of $46.7 million (95% CI, $43.8-$49.4 milli

198 tient-days, respectively, for a total yearly cost savings of $54656 for pharmacy purchasing data, $11

199 art Association guidelines lead to potential cost savings of $622 480.95 for the entire population.

200 LBHs and MBHs resulted in significantly more cost savings of $9155 per HBH patient, or $699 per patie

201 oth interventions could have resulted in ICU cost savings of 1.9 billion, representing a 6% reduction

202 Cost savings of 21% were realized in terms of waste disp

203 PR had a potential cost savings of 62% and 60.8% when compared to scleral b

204 onstrate the feasibility, acceptability, and cost savings of a stewardship program where resources ar

205 s appointment, there would be an incremental cost savings of A$5461 (US$4140) (95% CI, A$1433-A$10557

206 iary presentation resulted in an incremental cost savings of A$9020 (US$6838) per additional diagnosi

207 generic alternatives could have resulted in cost savings of as much as $118 million, or 70% of the t

208 61 000 OIs (2013 UNAIDS data) with estimated cost savings of at least US$17 million per year.

209 300 (95% CI: 68,700; 277,800) and healthcare cost savings of AU$1,733 million (m) (95% CI: $650m; $2,

210 The cost savings of avoiding lobectomy in patients with beni

211 The estimated annualized labor cost savings of culture using blood culture bottles was

212 Cost data did not indicate a definitive cost savings of either treatment method ($562 for in-off

213 At a disease prevalence of 75%, per-patient cost savings of empirical terbinafine therapy without co

214 e greatest current benefit of the ESP is the cost savings of high frequency, bio-surveillance at remo

215 equencing would be associated with estimated cost savings of over pound 728 290 per annual hospitaliz

216 Annual cost savings of pound5.5 to pound8.2 million ($7.3-$10.9

217 de it imperative to understand the potential cost savings of quality-improvement initiatives.

218 g model had significantly lower costs (total cost savings of S$173 per person) while generating simil

219 xtra 6.4 and 6.1 grafts would be saved, with cost savings of U.S. $867,203 and U.S. $830,664 per 100

220 In Uganda, cost savings of up to 62% were observed with a centraliz

221 The gross cost-savings of NSQIP were estimated at $11.4 million.

222 The cost-savings of NSQIP were estimated from the start of N

223 emyelinating neuropathy would lead to annual cost-savings of pound 107 398 for the National Health Se

224 ffectiveness and lesser cost, representing a cost-saving option over DPYD intermediate and poor metab

225 naive to treatment with biologicals, and is cost saving over 12 months.

226 ith Atlanta, Baltimore, and Miami projecting cost savings over the 20 year study period.

227 There was a cost saving per case of A$633,446 in 2010-2011 compared

228 averted more cases but cost more, decreasing cost savings per case averted.

229 treatment-related cost for CMV disease, net cost-savings per patient associated with PET was $8,707

230 fficient strategy which can lead to time and cost saving post-translational, covalent conjugation of

231 ology department and to estimate energy- and cost-saving potential during clinical operation.

232 Considerable energy- and cost-saving potential is present during nonproductive id

233 nd of the 15th year, would result in a total cost saving ( pound1.0 billion discounted), avert 25% of

234 Cost abatement curves display per unit cost savings related to overall direct and indirect ener

235 ieving an estimated 32.1% (95% CI 29.6-34.5) cost saving relative to adopting country-wide policies.

236 duction while providing substantial material cost savings relative to platinum.

237 proach produces substantial benefits and net cost savings relative to the status quo.

238 Only drug cost savings remained significant in multivariate analys

239 Quantifying these cost savings requires additional research, because there

240 As cost-saving results, the Subcommittee for Development of

241 Cost-saving short (50-bp) single-end reads and Nextera (

242 nts to allow for effective implementation of cost-saving strategies.

243 on COM importance, team-based screening, and cost-saving strategies.

244 A cost-saving strategy to diagnose other diseases is to po

245 qHPV vaccine after treatment for HGAIN is a cost-saving strategy.

246 tibiotic-sparing and cost-effective, or even cost-saving, strategy to reduce child mortality.

247 tment, providing greater health benefits and cost savings than the observed standard of care.

248 ith MAT+ at 80% was more expensive (eg, less cost saving) than MAT+ at 80% alone without DAA, it offe

249 with MAT+ 80% was more expensive (e.g., less cost-saving) than MAT+ 80% alone without DAA, it offered

250 To identify the mechanisms of potential cost savings, the frequency and amount of physician, rea

251 interventions ($2.6 million) from the gross cost-savings, the net cost-savings were $8.8 million.

252 s and assisted partner notification would be cost-saving; the cost per LYS would also be low in the c

253 5) What strategies can be used to promote cost savings through greater generic medication use?

254 THPP is relatively cheap to deliver and is cost-saving through reduced health-care, time and produc

255 Monitoring could be cost saving to society if monitoring reduced the frequen

256 ry for patients with obesity and T2DM-Ins is cost saving to the national healthcare provider (Nationa

257 cost-effectiveness ratio of $35663 (95% CI, cost savings to $235613) per quality-adjusted life-year

258 EP) would substantially shorten the time for cost savings to be realised.

259 ial data analysis indicates estimated annual cost savings to Geisinger Health Plan ranges from $247,0

260 eric medications offer substantial potential cost savings to health systems compared to their branded

261 ults in decreased mortality and a net annual cost savings to the insurer compared with usual care pro

262 xico, $364 (147 to 692) in Nigeria, and $64 (cost-saving to 203) in South Africa, amounting to 0.4-6.

263 decolonization, universal decolonization is cost-saving to cost-effective, with maximum cost savings

264 ide 95% CI from a negative value (suggesting cost savings) to $375,870.

265 lication of the NICE guidance, which assumed cost savings, to participants with CKD G3aA1 increased t

266 QALY gains and cost savings took 50 y to peak, owing to such factors as

267 ART in truly HIV-uninfected infants, it was cost-saving: total cost US$1,790/infant tested, compared

268 Estimated cost savings totaled $2.5M during the 2-year interventio

269 aintenance or 2-drug for ART-naive patients, cost savings totaled $550 million and $800 million, resp

270 Pasireotide appears to be a cost-saving treatment following PD across a wide variati

271 Kidney transplantation is a cost-saving treatment that extends the lives of patients

272 Confirmatory testing remained cost-saving unless NAAT cost exceeded US$400 or the HIV-

273 and 39%, respectively, over 100 years and is cost saving (vs.

274 and 39%, respectively, over 100 years and is cost saving (vs.

275 The average monthly asthma-related cost savings was $34.02/mo (95% CI, $5.42/mo to $61.24/m

276 Institutional cost savings was estimated at $27000 per year.

277 Cost savings was more prominent amongst high-risk patien

278 Furthermore, a positive institutional cost savings was observed.

279 lysis showed the probability for NSQIP to be cost-saving was 95%.

280 Beyond time and cost savings, we also show ERASE can assort molecules ba

281 To calculate the net cost-savings, we deducted the costs of NSQIP and its int

282 Cost savings were also observed in the Sepsis-3 group.

283 were employed to determine significance, and cost savings were estimated based on our internal costs.

284 l ID consults were tracked and antimicrobial cost savings were estimated.

285 consultations were tracked and antimicrobial cost savings were estimated.

286 illion) from the gross cost-savings, the net cost-savings were $8.8 million.

287 and third-party payer perspective, DMEK was cost-saving when compared with DSAEK in improving visual

288 For removal sampling, the largest cost savings while maintaining unbiased density estimate

289 s hospitalized for more than 3 days and in a cost savings while retaining the ability of the clinicia

290 undue focus on administrative efficiency and cost savings will not necessarily guarantee cutting-edge

291 ther agent progressed from cost incurring to cost saving with increasing generic market share.

292 Our data strongly suggest potential cost savings with fondaparinux and underscore the critic

293 lacement (LEJR) are associated with 2% to 4% cost savings with stable quality among Medicare fee-for-

294 of hospitalisation, the CIMIC programme was cost-saving with a probability of 70% under both the low

295 ore, DMEK was the dominant procedure and was cost-saving with respect to DSAEK.

296 was associated with a lower rate of MACE and cost savings, with a threshold effect at >80% adherence

297 USD 6,730 to 17,720), HCV treatment would be cost-saving within a 5 to 20-year time horizon, which sh

298 ffice-based setting could yield considerable cost savings without adversely affecting health outcomes

299 ignificant reductions in ICU albumin use and cost savings without changes in patient outcomes, suppor

300 These cost-savings would be even larger if NSQIP was prolonged